GlaxoSmithKline sees better signs for lung drugs after tough 2014
February 04, 2015 at 07:16 AM EST
LONDON, Feb 4 (Reuters) - GlaxoSmithKline said on Wednesday it expected to start to regain market share in respiratory medicine after weak demand for lung drug Advair again hurt fourth-quarter sales, capping a rough year for Britain's top drugmaker.